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Abstract
Introduction: Anemia and renal impairment are important co-morbidities among
patients with coronary artery disease undergoing Percutaneous Coronary
Intervention (PCI). Disease progression to eventual death can be understood as the
combined effect of baseline characteristics and intermediate outcomes.
Methods: Using data from a prospective cohort study, we investigated clinical
pathways reflecting the transitions from PCI through intermediate ischemic or
hemorrhagic events to all-cause mortality in a multi-state analysis as a function of
anemia (hemoglobin concentration ,120 g/l and ,130 g/l, for women and men,
respectively) and renal impairment (creatinine clearance ,60 ml/min) at baseline.
Results: Among 6029 patients undergoing PCI, anemia and renal impairment were
observed isolated or in combination in 990 (16.4%), 384 (6.4%), and 309 (5.1%)
patients, respectively. The most frequent transition was from PCI to death (6.7%,
95% CI 6.1–7.3), followed by ischemic events (4.8%, 95 CI 4.3–5.4) and bleeding
(3.4%, 95% CI 3.0–3.9). Among patients with both anemia and renal impairment,
the risk of death was increased 4-fold as compared to the reference group (HR 3.9,
95% CI 2.9–5.4) and roughly doubled as compared to patients with either anemia
(HR 1.7, 95% CI 1.3–2.2) or renal impairment (HR 2.1, 95% CI 1.5–2.9) alone.
Hazard ratios indicated an increased risk of bleeding in all three groups compared
to patients with neither anemia nor renal impairment.
Conclusions: Applying a multi-state model we found evidence for a gradient of risk
for the composite of bleeding, ischemic events, or death as a function of
hemoglobin value and estimated glomerular filtration rate at baseline.
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Introduction
Patients with coronary artery disease undergoing revascularization are often found
to have anemia and renal impairment. Both conditions are independently
associated with increased risk of bleeding, ischemic events, and mortality [1–9].
Anemia and renal impairment may be directly causally related, or they may be a
marker of underlying morbidities. Both conditions are associated with established
cardiovascular risk factors, such as age, gender and diabetes, and may coexist in
the absence of a direct causal relationship, which is observed in 10 to 25% of
patients undergoing percutaneous coronary intervention (PCI) for stable
coronary artery disease or acute coronary syndromes [1–3, 7]. Routine assessment
of haemoglobin and glomerular filtration rate in patients undergoing PCI may not
only have immediate implications for the peri-procedural management, but may
also provide a useful tool to approximate progression of disease after PCI. The
combined effect of anemia and renal impairment on long-term clinical outcome
has not been investigated in large cohorts. Our objective was to estimate long-
term mortality associated with anemia and renal impairment, separately and in
combination, while also accounting for the most relevant intermediate outcomes,
such as bleeding or ischemic events. We used data from a prospective registry of
patients undergoing PCI with the unrestricted use of drug eluting stents (DES) to
provide novel insights by quantifying transition-specific risk estimates.
Methods
Patient Population and Inclusion Criteria
Between April 2002 and March 2009, a total of 6300 patients underwent 6529
interventions with the unrestricted use of early and newer generation DES at Bern
University Hospital, Switzerland, and were prospectively entered into the Bern
DES registry. A total of 229 patients received both early and newer generation DES
at two different points in time. We considered the first intervention as eligible for
the reporting of the baseline characteristics and for this analysis in general.
Patients who had missing information regarding the implanted stent (n55),
missing hemoglobin values at baseline (n5193), or had not undergone follow-up
after the index procedure (n574) were excluded, resulting in 6029 subjects for the
purpose of the present analysis.
Data Collection
In the DES registry, demographic information and clinical characteristics such as
type of stent implanted and related PCI information was collected systematically.
Laboratory values were retrieved from the local central hematology and chemistry
laboratory, including hemoglobin and hematocrit values on admission, as well as
creatinine at baseline. In-hospital outcome data were captured from the electronic
hospital records. Subsequently, data on vital status were recorded for all patients
from hospital records and municipal civil registries, and a postal questionnaire
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was sent to all living patients with questions on re-hospitalization and major
adverse cardiovascular events. Patients, general practitioners and referring
cardiologists were contacted by telephone in case of non-response or if additional
information was required. In case of suspected cardiovascular events, medical
records, discharge letters, and coronary angiography documentation were
systematically collected and reviewed.
Ethics Statement
The registry was approved by the institutional ethics committee at Bern University
Hospital, Switzerland (www.kek-bern.ch), and complied with the Declaration of
Helsinki. Written informed consent was given by the patients for their
information to be stored in the hospital database and used for research.
Procedures
PCI was performed according to practice guidelines that applied at the time of
stent implantation. During intervention, unfractionated heparin in a dose of 5000
IU or 70–100 IU/kg was administered targeting an activated clotting time of
.250 seconds. Before or at the time of the procedure, dual antiplatelet therapy
was initiated with acetylsalicylic acid $100 mg and clopidogrel 300–600 mg;
while clopidogrel was recommended to be continued for the duration of at least
12 months, acetylsalicylic acid was prescribed lifelong. Peri-procedural adminis-
tration of glycoprotein IIb/IIIa inhibitors was left to the discretion of the operator.
Before and after the procedure a 12-lead electrocardiogram was obtained and
cardiac enzymes were assessed within 24 hours of the procedure. In addition to
routine assessment of creatinine kinase (CK), CK-MB and troponin T, repeat
measurements of these markers were performed every 6–8 hours in patients with
suspected ischemia until the peak level was identified.
Definitions
Categorization of anemia was performed in accordance with the definition
provided by the World Health Organization (WHO), defining anemia as a
hemoglobin concentration ,120 g/l in women and ,130 g/l in men [10].
Patients were classified to have renal impairment if there was moderate renal
insufficiency as defined by an eGFR according to the Cockroft-Gault formula of
,60 ml/min [11]. Creatinine levels and weight at baseline were used to estimate
glomerular filtration rate (eGFR). Bleeding events were classified according to the
consensus report from the Bleeding Academic Research Consortium (BARC)
definition [12]. Myocardial infarction (MI) included Q-wave and non-Q-wave MI
and was diagnosed in the setting of symptoms or signs of ischemia in the presence
of new pathological Q-waves in $2 contiguous leads, or an elevation in CK to
$2x the upper reference limit (URL) and a rise in CK-MB, or troponin to $3x
URL in the presence of ischemic symptoms or ECG changes. Cerebrovascular
events were reviewed and adjudicated by two board certified neurologists (SJ,
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HM). Ischemic stroke was diagnosed in case of a focal neurological deficit (motor
or sensory deficit, dysarthria, aphasia, visual loss) with duration of $24 hours
and/or imaging documentation of ischemia and exclusion of intracranial bleeding.
Ischemic events (IE) were defined as the composite of myocardial infarction or
ischemic stroke. Death comprises both cardiovascular (CV) and non-cardiovas-
cular (non-CV) death and was considered as the primary outcome throughout the
present analysis. All potential events were centrally adjudicated based on relevant
medical records. Only the first event of each type of clinical outcome was used for
this analysis. The duration of observation was defined as time from PCI to death
or end of follow-up up to four years, without censoring at the time of occurrence
of an intermediate outcome.
Statistical analysis
Disease progression to eventual death can be understood as the combined effect of
baseline characteristics and intermediate outcomes. Considering both the
intermediate outcomes and the final endpoint, we identified four stages (PCI,
bleeding, ischemic events and death), resulting in six stage-to-stage transitions a
patient could undergo from PCI to death or end of follow up. The four stages and
the corresponding transitions are illustrated in Fig. 1. Transitions from PCI to
bleeding, ischemic events and death were referred to as primary transitions (T1 to
T3). Further transitions from bleeding to ischemic events and death were defined
as secondary transitions (T4 to T6). We ignored possible recurrent transitions, e.g.
from ischemic events to bleeding or re-intervention due to the low number of
observations (n53) and the missing corresponding baseline characteristics,
respectively. We performed a continuity correction in case two events occurred on
the same day.
All analyses were performed in order to compare the four target subgroups:
patients with anemia only, patients with renal impairment only, patients with
both conditions, and patients with neither condition at baseline (reference group).
We assessed the additivity of the two conditions by comparing different Cox
proportional hazard models on the primary outcome using the likelihood ratio
test. The first two models include only one variable, informing about the presence
of either anemia or renal impairment. The third model includes both conditions
while the fourth model considers additionally the interaction between the two
conditions. The non-significant interaction term was interpreted as lack of
evidence for a synergetic effect of the two conditions [13–16]. Furthermore, the
additive effect of anemia and renal impairment was also estimated using a
weighted random effects regression model across ordered groups. The ordering of
the groups is based on the x2-statistic of different Cox proportional hazard
regressions of the primary outcome, death, using all possible orders of the groups.
Baseline and procedural characteristics were compared between subgroups
using logistic or multinomial regression for categorical and linear regression
analysis for continuous variables. We compared the number of transitions among
the four subgroups using multinomial logistic regression. We estimated the
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hazards for each of these transitions and calculated transition-specific hazard
ratios for each subgroup using Cox proportional hazard models within a multi-
state analysis (MSA) [17]. MSA allows us to describe the transition from PCI
through intermediate clinical outcomes (bleeding and ischemic events such as
myocardial infarction, ischemic stroke and definite stent thrombosis) to eventual
death. We use MSA to estimate all-cause mortality because the intermediate
events might change the risk of the endpoint to occur and can be treated as
competing intermediate risks. The intermediate events provide more information
on the disease progression and considering them allows for more precision in
predicting the disease progression [18]. The model allowed for different baseline
hazards for each transition and adjusted for type of stent (early versus newer
generation DES), age, gender, diabetes, hypertension, dyslipidemia, left ven-
tricular ejection function (LVEF) and acute coronary syndrome (ACS). Results are
presented as transition-specific hazard ratios (HR) with 95% confidence intervals
(CI). Based on transition-specific hazards, we predicted the transition probability,
defined as the probability of a particular event at a given time point for the four
target subgroups. We estimate the trend using linear weighted random effects.
Fig. 1. illustrates the four stages of disease included into the multi-state analysis and the six stage-to-stage transitions a patient may experience
from the time of PCI to death or end of follow-up.
doi:10.1371/journal.pone.0114846.g001
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Analyses were performed using R version 3.1 (The R Development Core Team,
Vienna, Austria) using the mstate package [17] and STATA version 13.1.
Results
A total of 6029 subjects undergoing PCI with the unrestricted use of early and
newer generation DES were considered for the present analysis. Both anemia and
renal impairment were present in 309 (5.1%), anemia only in 990 (16.4%), renal
impairment only in 384 (6.4%), and neither anemia nor renal impairment
(reference group) in 4346 patients (72.1%). The median follow-up of the overall
cohort amounted to 3.2 years (interquartile range [IQR] 2.3–4.1 years). The
median follow-up was 3.2 years (IQR 2.4–4.1) in the reference group, 3.0 years
(IQR 2.1–4.0) among patients with anemia only, 3.3 years (IQR 2.3–4.1) among
patients with renal impairment only, and 2.7 years (IQR 1.7–3.8) among patients
with both anemia and renal impairment. The association between the subgroups
and the median duration of follow-up was statistically significant (p,0.001).
Baseline and procedural characteristics
Baseline characteristics are summarized in Table 1, with statistically significant
differences between all characteristics across subgroups. Patients in the two
subgroups with renal impairment (with and without anemia) were older, more
often female and had a higher prevalence of hypertension. Table 2 presents
procedural characteristics.
Transitions
Table 3 reports numbers of patients according to subgroup and stage, who
experienced different transitions up to four years of follow-up. The most frequent
transitions were PCI to ischemic events and PCI to death. The most probable
transitions once having reached a specific stage were observed in patients with
both anemia and renal impairment, with transition T5 from bleeding to death and
T6 from ischemic events to death. If patients with both conditions experienced a
bleeding event they had a 43% probability of death at four years (95% CI 25–63);
if they experienced an ischemic event they had a 20% probability of death (95%
CI 4–48). A similar, albeit attenuated pattern was observed for patients with renal
impairment only, with a 39% probability of death in patients with a bleeding
event (transition T5, 95% CI 20–61) and a 25% probability of death in patients
with an ischemic event (transition T6, 95% CI 8–49).
Fig. 2 presents the multi-state model illustrating transition-specific adjusted
hazard ratios for the three specific groups of patients with anemia only, renal
impairment only, and anemia and renal impairment with the reference group. In
patients with both conditions the risk of death (HR 3.9, 95% CI 2.9–5.4) was
increased 4-fold as compared to the reference group and higher as compared to
patients with either anemia or renal impairment alone. Hazard ratios indicated an
PCI Multistate Analysis
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increased risk for bleeding and death in all three groups compared to the reference
group. Moreover, patients with anemia alone had a higher probability to have an
ischemic event after PCI (HR 1.4, 95% CI 1.0–2.0) but a lower probability to die
after an ischemic event compared to the reference group (HR 0.1, 95% CI 0.0–
0.8). Fig. 3 summarizes the adjusted transition-specific hazard ratios for the three
patient subgroups compared to the reference group.
Additive effect of anemia and renal impairment
As described above, the additive effect of anemia and renal impairment is
evaluated using different methods. In Fig. 3, we show that the additivity of anemia
and renal impairment is statistically significant for the transition from PCI to
bleeding (p,0.001), and from PCI to the primary outcome death (p,0.001),
estimated using ordered groups. This trend across ordered groups is also
illustrated in the corresponding forest plot. Table 4 presents further analyses of
the additive effect of the two conditions. Both the AIC and the likelihood ratio
tests of the comparison of the different models indicate that the additive model
Table 1. Baseline characteristics.
Baseline characteristics Reference
Anemia
only
Renal
impairment only
Both anemia and renal
impairment
p-value for differences
across groups
Total (n) 4346 990 384 309
Age (yr [SD]) 61.8 (11.3) 66.3 (11.1) 71.5 (9.3) 72.4 (10.1) ,0.001
Men (n [%]) 3445 (79.3) 716 (72.3) 224 (58.3) 163 (52.8) ,0.001
BMI (mean [SD]) 27.4 (4.2) 26.4 (4.4) 27.8 (4.8) 27.6 (4.8) ,0.001
Hypertension (n [%]) 2407 (55.5) 575 (58.6) 273 (71.5) 221 (71.8) ,0.001
Dyslipidemia (n [%]) 2401 (55.4) 487 (49.6) 203 (53.1) 137 (44.5) ,0.001
Diabetes mellitus (n [%]) 644 (14.9) 227 (23.1) 92 (24.1) 99 (32.1) ,0.001
Smoking at baseline (n [%]) 2385 (55.0) 463 (47.1) 147 (38.5) 103 (33.4) ,0.001
Left ventricular ejection fraction, ,30% (n [%]) 77 (1.8) 28 (3.1) 18 (5.2) 17 (6.5) ,0.001
Acute coronary syndrome (n [%]) 2281 (52.5) 640 (64.6) 163 (42.6) 152 (49.2) ,0.001
ST-elevation MI (n [%]) 1202 (52.8) 365 (57.0) 91 (56.2) 63 (41.7) 0.006
Second generation stent (n [%]) 1450 (33.4) 406 (41.0) 110 (28.6) 131 (42.4) ,0.001
Type of stent (n [%]) ,0.001
PES 961 (22.1) 186 (18.8) 89 (23.2) 58 (18.8)
SES 1935 (44.5) 398 (40.2) 185 (48.2) 120 (38.8)
ZES 498 (11.5) 107 (10.8) 41 (10.7) 44 (14.2)
EES 952 (21.9) 299 (30.2) 69 (18.0) 87 (28.2)
Hgb on admission (mean [SD]) 144.5 (11.2) 115.6 (12.0) 140.5 (11.6) 109.8 (11.8) ,0.001
Htc on admission (mean [SD]) 0.4 (1.0) 0.3 (0.0) 0.4 (0.0) 0.3 (0.0) 0.001
Creatinine (mean [SD]) 76.4 (14.6) 75.7 (16.1) 133.5 (78.0) 175.9 (136.0) ,0.001
Reference category: No anemia and no renal impairment.
doi:10.1371/journal.pone.0114846.t001
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(model 3) has the best goodness of fit. This in turn is evidence that the effects of
anemia and renal impairment are additive. Finally, using weighted random effects
regression we show in Table 5 that the additivity of the two conditions can best be
demonstrated for our primary outcome, death, as well as the composite of the
events.
Table 2. Procedural characteristics.
Procedural
characteristics Reference
Anemia
only
Renal
impairment
only
Both anemia
and renal
impairment
p-value for
differences
across groups
Total (n) 4346 990 384 309
Multivessel
treatment (n [%])
829 (19.1) 193 (19.5) 64 (16.7) 76 (24.8) 0.054
Number of vessels
treated per patient (n [SD])
1.2 (0.4) 1.2 (0.4) 1.2 (0.4) 1.3 (0.5) 0.72
Number of lesions
treated per patient (n [SD])
1.6 (0.8) 1.6 (0.9) 1.5 (0.8) 1.7 (0.9) 0.121
Target vessel - number
of patients (n [%])
Left main 89 (2.1) 43 (11.2) 17 (4.4) 23 (7.5) ,0.001
Left anterior
descending
2181 (50.3) 446 (45.1) 196 (51.0) 146 (47.6) 0.025
Left circumflex 1148 (26.5) 254 (25.7) 86 (22.4) 87 (28.3) 0.276
Right coronary artery 1494 (34.4) 401 (40.6) 127 (33.1) 101 (32.9) 0.002
Arterial bypass graft 9 (0.2) 3 (0.3) 0 (0.0) 2 (0.7) 0.33
Saphenous vein graft 115 (2.7) 25 (2.5) 12 (3.1) 15 (4.9) 0.136
Number of stents
implanted (n [SD])
1.8 (1.0) 1.8 (1.0) 1.7 (1.0) 1.9 (1.1) 0.176
Average stent
diameter (n [SD])
2.9 (0.5) 2.9 (0.4) 2.8 (0.4) 2.8 (0.4) 0.011
Total stent length
per patient (n [SD])
29.9 (18.0) 31.1 (19.0) 28.7 (17.1) 32.6 (20.6) 0.008
Glycoprotein IIb/IIIa
antagonist (n [%])
993 (22.8) 276 (27.9) 49 (12.8) 43 (13.9) ,0.001
Medication at
discharge (n [%])
Aspirin 4217 (97.1) 954 (96.4) 354 (92.9) 283 (92.2) ,0.001
Clopidogrel 4254 (98.2) 965 (97.8) 360 (94.5) 290 (95.1) ,0.001
Oral anticoagulation 71 (1.6) 21 (2.1) 17 (4.5) 13 (4.3) ,0.001
Betablocker 2681 (61.9) 623 (63.1) 228 (59.8) 185 (60.7) 0.681
ACE inhibitor 2303 (53.2) 549 (55.6) 176 (46.2) 128 (42.0) ,0.001
AT II inhibitor 570 (13.2) 153 (15.5) 89 (23.4) 75 (24.6) ,0.001
Calcium antagonist 409 (9.4) 92 (9.3) 57 (15.0) 52 (17.0) ,0.001
Statin 3760 (86.8) 815 (82.6) 292 (76.6) 223 (73.1) ,0.001
Diuretics 602 (13.9) 212 (55.6) 132 (34.6) 103 (33.8) ,0.001
Reference category: No anemia and no renal impairment.
doi:10.1371/journal.pone.0114846.t002
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Estimated probabilities of clinical outcomes
Fig. 4 illustrates the results of the multi-state model from index PCI up to four
years of follow-up; the corresponding confidence intervals are displayed in
Table 5. At four years, the probability of at least one event was 17.3% in the
reference group without anemia nor renal impairment (95% CI 16.2–18.4), 23.4%
in patients with anemia only (95% CI 20.4–26.4), 28.0% in patients with renal
impairment only (95% CI 22.9–33.2) and 41.8% in patients with both anemia and
renal impairment (95% CI 35.4–48.2).
Discussion
We estimated the risk for specific transitions through intermediate adverse events
that characterize progression of disease after PCI and modeled clinical outcomes
as a function of anemia and renal impairment at baseline. The two conditions
were encountered isolated or in combination in one in every four patients in a
consecutive cohort of patients with coronary artery disease undergoing PCI. We
found a strong gradient of risk for the composite of bleeding, ischemic events, or
death as a function of hemoglobin value and estimated glomerular filtration rate
at baseline. Presence of both, anemia and renal impairment increased the risk of
clinical adverse events throughout four years after PCI to 42%. The risk of death
was approximately 5-fold increased as compared to patients with neither anemia
nor renal impairment, and almost doubled or tripled as compared to patients with
either isolated renal impairment or anemia, respectively. Assessing the interaction
Table 3. Transition-specific event rates by anemia and renal impairment, N56029.
Transitions Reference
Anemia
only
Renal
impairment
only
Both anemia
and renal
impairment
p-value for
differences
across groups
PCI (S1): 4346 990 384 309 ,0.001
T1: PCI to bleeding (S2) 99 (2.3) 56 (5.7) 23 (6.0) 30 (9.7)
T2: PCI to ischemic
events (S3)
197 (4.5) 59 (6.0) 20 (5.2) 14 (4.5)
T3: PCI to death (S4) 196 (4.5) 90 (9.1) 49 (12.8) 68 (22.0)
No event 3854 (88.7) 785 (79.3) 292 (76.0) 197 (63.8)
Bleeding (S2): 99 56 23 30 0.005
T4: Bleeding to ischemic
events (S3)
8 (8.1) 4 (7.1) 0 (0.0) 1 (4.3)
T5: Bleeding to death (S4) 10 (10.1) 10 (17.9) 9 (39.1) 13 (43.3)
No event 81 (81.8) 42 (75.0) 14 (60.9) 16 (53.3)
Ischemic events (S3): 205 63 20 15 0.019
T6: Ischemic events to
death (S4)
18 (8.8) 1 (1.6) 5 (25.0) 3 (20.0)
No event 187 (91.2) 62 (98.4) 15 (75.0) 12 (80.0)
Reference category: No anemia and no renal impairment.
Displayed numbers in column 2–5 represent frequencies (%).
doi:10.1371/journal.pone.0114846.t003
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Fig. 2. shows a multi-state model depicting transition-specific adjusted hazard ratios with 95% CI by anemia and renal impairment.
doi:10.1371/journal.pone.0114846.g002
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between anemia and renal impairment we were able to show that the combination
of the two conditions does not lead to an effect modification of one of the isolated
conditions, but that their effects are additive.
The multi-state methodology applied in our analysis provides a holistic
approach to clinical outcome assessment and accounts for progression of disease
along a pathway through intermediate clinical events to eventual death. We
observed a gradient of risk for clinical adverse events defined by the presence of
the two conditions anemia and renal impairment isolated or in combination,
respectively. Risk estimates were derived from an integrated analysis of all types of
clinical outcome events and all occurring transitions from stage to stage. This
approach is novel as compared to a traditional analysis, in which each outcome
event is decontextualized, isolated from associated intermediate events. The
magnitude of risk may thus be underestimated in traditional analysis. We avoided
this limitation by modeling the progression of the disease through all stages.
Fig. 3. shows the transition-specific adjusted hazard ratios with 95% CI according to anemia and renal impairment using Cox proportional hazard
models within a multi-state analysis. Adjustment for type of stent, age, gender, diabetes, hypertension, dyslipidemia, LV function, acute coronary
syndrome. Reference: patients with no renal impairment and no anemia. P-value for trend estimated considering ordered groups.
doi:10.1371/journal.pone.0114846.g003
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Our analysis is weakened by a relatively small number of events per transition,
in particular for secondary transitions from an intermediate event to eventual
death, which made precise estimates of relative and absolute risks difficult for
some of the transitions. Along the line, we found a lower risk of death after an
ischemic event among patients with anemia only as compared to the reference
group, which is likely to be related to the low number of observations for this
secondary transition. In turn, the analysis was based on a consecutive cohort of
unselected patients with nearly complete follow-up and centralized adjudication
of clinical events.
Our analysis corroborates a high prevalence rate of anemia and renal
impairment among patients with coronary artery disease. Approximately one
quarter of patients undergoing PCI [1–3, 7] have been detected with renal
impairment and/or anemia in previous reports. Both clinical entities are causally
related to the development of coronary artery disease and myocardial ischemia,
respectively, thereby explaining the high prevalence in this patient population. In
addition, anemia and renal impairment were separately associated with increased
long-term mortality following revascularization. Moderate renal impairment has
been shown to increase all-cause mortality two-fold in a study of 11952 patients
with coronary artery disease during a mean follow-up period of 3.6¡2.2 years [7].
Table 4. Model comparison for the evaluation of additivity of anemia and renal impairment.
Model AIC
x2-statistic of
model
p.x2 of
model x2-statistic of comparison
p.x2 of
comparison
1) Anemia only 6777.29 LR x2 (1): 75.81 ,0.001 LR x2 (1) model 1 vs. null model:
75.81
,0.001
2) Renal impairment only 6750.89 LR x2 (1): 102.21 ,0.001 LR x2 (1) model 2 vs. null model:
102.21
,0.001
3) Additive effect of anemia and renal impairment 6707.43 LR x2 (2): 147.67 ,0.001 LR x2 (1) model 3 vs. model 2: 45.46 ,0.001
4) Multiplicative interaction: anemia x renal impair-
ment
6709.37 LR x2 (3): 147.73 ,0.001 LR x2 (1) model 4 vs. model 3: 0.06 0.810
The first two models are compared to the null model, while model 3 is compared to model 2 (higher x2-statistic as model 1) and model 4 to model 3 (higher
x2-statistic as model 2).
doi:10.1371/journal.pone.0114846.t004
Table 5. Predicted probabilities and 95% CI.
Transitions Reference Anemia only
Renal impairment
only
Both anemia and renal
impairment
p-value for trend across
ordered groups
To bleeding (S2) 1.9 (1.5–2.3) 3.9 (2.5–5.4) 3.8 (1.7–5.8) 5.4 (2.7–8.2) 0.068
To ischemic events (S3) 5.0 (4.3–5.8) 6.8 (5.1–8.4) 4.1 (1.9–6.3) 4.1 (1.4–6.8) 0.589
To death (S4) 6.2 (5.4–7.0) 12.7 (10.2–15.2) 20.2 (15.5–24.9) 32.2 (26.2–38.3) 0.009
Total events 13.1 (12.0–14.3) 23.4 (20.4–26.4) 28.0 (22.9–33.2) 41.8 (35.4–48.2) 0.009
Reference category: No anemia and no renal impairment.
Displayed numbers in column 2–5 represent predicted probabilities from multi-state Cox regression model (95% CI).
P-value for trend across ordered groups from weighted random effects regression.
doi:10.1371/journal.pone.0114846.t005
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Severe anemia was associated with a similar mortality risk increase (HR 2.02, 95%
CI 1.53–2.67) in a study of 6312 patients during a mean follow-up of 3.1¡0.8
years [19]. In the present MSA we found a strong combined effect of anemia and
renal impairment along a gradient of risk for clinical adverse events that was
particularly driven by mortality.
Conclusion
Applying a multi-state model we found evidence for a gradient of risk for the
composite of bleeding, ischemic events, or death as a function of hemoglobin
value and estimated glomerular filtration rate at baseline.
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